MCID: BRS049
MIFTS: 51

Breast Carcinoma in Situ

Categories: Cancer diseases, Genetic diseases, Immune diseases, Rare diseases, Reproductive diseases, Skin diseases

Aliases & Classifications for Breast Carcinoma in Situ

MalaCards integrated aliases for Breast Carcinoma in Situ:

Name: Breast Carcinoma in Situ 12 15
Carcinoma in Situ of Breast 12 32
Non-Infiltrating Carcinoma of Breast 12

Classifications:



External Ids:

Disease Ontology 12 DOID:8791
ICD9CM 34 233.0
SNOMED-CT 67 189336000
ICD10 32 D05 D05.9
UMLS 71 C0154084

Summaries for Breast Carcinoma in Situ

Disease Ontology : 12 An in situ carcinoma that is located in the breast.

MalaCards based summary : Breast Carcinoma in Situ, also known as carcinoma in situ of breast, is related to lobular neoplasia and ductal carcinoma in situ. An important gene associated with Breast Carcinoma in Situ is ERBB2 (Erb-B2 Receptor Tyrosine Kinase 2), and among its related pathways/superpathways are Signaling by GPCR and Apoptotic Pathways in Synovial Fibroblasts. The drugs Medroxyprogesterone acetate and mometasone furoate have been mentioned in the context of this disorder. Affiliated tissues include breast, testes and lymph node, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Breast Carcinoma in Situ

Diseases in the Breast Cancer family:

Inflammatory Breast Carcinoma Sporadic Breast Cancer
Breast Carcinoma in Situ

Diseases related to Breast Carcinoma in Situ via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 350)
# Related Disease Score Top Affiliating Genes
1 lobular neoplasia 33.2 TP53 PGR ESR1 ERBB2 BRCA2 BRCA1
2 ductal carcinoma in situ 33.1 VEGFA TP53 PGR ESR1 ERBB2 BRCA2
3 comedo carcinoma 33.1 TP53 PGR ESR1 ERBB2
4 in situ carcinoma 31.8 TP53 PGR ESR1 ERBB2 BRCA2 BRCA1
5 breast ductal carcinoma 30.8 VEGFC VEGFA TP53 PGR MET KRT19
6 tubular adenocarcinoma 30.6 PGR ESR1 ERBB2
7 mammary paget's disease 30.6 PGR ESR1 ERBB2
8 breast cancer 30.4 VEGFC VEGFA TP53 PGR MET KRT19
9 female breast cancer 30.4 TP53 PGR ESR1 ERBB2 BRCA2 BRCA1
10 breast fibroadenoma 30.4 VEGFC TP53 PGR ESR1 ERBB2 BRCA1
11 breast disease 30.2 VEGFA TP53 PGR KRT19 ESR1 ERBB2
12 neuroblastoma 29.9 VEGFA TP53 MET KDR IL6 FGFR1
13 ovarian cancer 29.3 VEGFC VEGFA TP53 PGR MET KDR
14 breast apocrine carcinoma in situ 12.0
15 fallopian tube clear cell adenocarcinoma 10.8 BRCA2 BRCA1
16 rare malignant breast tumor 10.7 BRCA2 BRCA1
17 ovary transitional cell carcinoma 10.7 BRCA2 BRCA1
18 hereditary site-specific ovarian cancer syndrome 10.7 BRCA2 BRCA1
19 septate uterus 10.7 KDR FLT1
20 mutagen sensitivity 10.7 TP53 BRCA2 BRCA1
21 peritoneum cancer 10.7 TP53 BRCA2 BRCA1
22 tetraploidy 10.7 BRCA2 BRCA1
23 cancerophobia 10.7 BRCA2 BRCA1
24 carcinosarcoma 10.7 TP53 PGR ERBB2
25 hemifacial spasm 10.7 VEGFA FLT4
26 synchronous bilateral breast carcinoma 10.7 PGR BRCA2 BRCA1
27 myasthenic syndrome, congenital, 6, presynaptic 10.7 TP53 BRCA2 BRCA1
28 familial ovarian cancer 10.7 ESR1 BRCA2 BRCA1
29 gastric papillary adenocarcinoma 10.7 TP53 ERBB2
30 scirrhous adenocarcinoma 10.7 PGR ERBB2
31 angiokeratoma of mibelli 10.7 KDR FLT1
32 radiation proctitis 10.7 VEGFA KDR FGF2
33 proctitis 10.7 VEGFA KDR FGF2
34 nosophobia 10.7 BRCA2 BRCA1
35 pediatric angiosarcoma 10.7 VEGFA TP53
36 ovarian carcinosarcoma 10.7 TP53 ERBB2 BRCA2 BRCA1
37 apocrine adenosis of breast 10.7 TP53 PGR ERBB2
38 ovarian cystadenoma 10.7 TP53 CLDN4 BRCA1
39 breast adenoid cystic carcinoma 10.7 TP53 PGR ERBB2
40 background diabetic retinopathy 10.7 VEGFA KDR IL6
41 breast sarcoma 10.7 TP53 PGR ERBB2
42 subacute thyroiditis 10.7 VEGFA IL6 FGF2
43 epithelioid hemangioendothelioma 10.7 VEGFA KDR FLT1
44 endometrial squamous cell carcinoma 10.7 TP53 PGR
45 angiokeratoma circumscriptum 10.7 VEGFA KDR FLT1
46 breast angiosarcoma 10.7 VEGFA KDR FLT4
47 decubitus ulcer 10.7 VEGFA IL6 FGF2
48 primary cutaneous b-cell lymphoma 10.7 VEGFA KDR FLT1
49 gastroesophageal adenocarcinoma 10.7 MET KDR ERBB2
50 bartholin's gland adenoid cystic carcinoma 10.7 PGR ESR1

Graphical network of the top 20 diseases related to Breast Carcinoma in Situ:



Diseases related to Breast Carcinoma in Situ

Symptoms & Phenotypes for Breast Carcinoma in Situ

GenomeRNAi Phenotypes related to Breast Carcinoma in Situ according to GeneCards Suite gene sharing:

26 (show all 16)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 9.66 ESR1 FGFR1 KDR
2 Decreased viability GR00221-A-2 9.66 BRCA1 ESR1 FGFR1 FLT1 FLT4 KDR
3 Decreased viability GR00221-A-3 9.66 BRCA1 KDR
4 Decreased viability GR00221-A-4 9.66 ESR1 KDR
5 Decreased viability GR00249-S 9.66 KDR
6 Decreased viability GR00301-A 9.66 BRCA1
7 Decreased viability GR00342-S-1 9.66 FLT4
8 Decreased viability GR00342-S-2 9.66 FLT4
9 Decreased viability GR00342-S-3 9.66 FLT4
10 Decreased viability GR00386-A-1 9.66 ESR1 FGFR1 FLT4
11 Decreased viability GR00402-S-2 9.66 ESR1
12 Decreased substrate adherent cell growth GR00193-A-1 9.35 MET
13 Decreased substrate adherent cell growth GR00193-A-3 9.35 MET
14 Decreased substrate adherent cell growth GR00193-A-4 9.35 FGFR1 KDR MET
15 Decreased cell migration GR00055-A-1 9.33 FLT1 MET
16 Decreased cell migration GR00055-A-3 9.33 SDC1

MGI Mouse Phenotypes related to Breast Carcinoma in Situ:

45 (show all 25)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.55 BRCA1 CLDN4 ERBB2 ESR1 FGF2 FGFR1
2 cellular MP:0005384 10.54 BRCA1 BRCA2 CLDN4 ERBB2 ESR1 FGF2
3 homeostasis/metabolism MP:0005376 10.54 BRCA1 BRCA2 CLDN4 ERBB2 ESR1 FGF2
4 immune system MP:0005387 10.48 BRCA1 BRCA2 ESR1 FGFR1 FLT1 FLT4
5 behavior/neurological MP:0005386 10.47 BRCA1 BRCA2 ERBB2 ESR1 FGF2 FGFR1
6 mortality/aging MP:0010768 10.47 BRCA1 BRCA2 CLDN4 ERBB2 ESR1 FGF2
7 growth/size/body region MP:0005378 10.45 BRCA1 BRCA2 CLDN4 ERBB2 ESR1 FGFR1
8 embryo MP:0005380 10.44 BRCA1 BRCA2 ERBB2 ESR1 FGFR1 FLT1
9 hematopoietic system MP:0005397 10.44 BRCA1 BRCA2 CLDN4 ESR1 FGF2 FGFR1
10 integument MP:0010771 10.41 BRCA1 BRCA2 ERBB2 ESR1 FGFR1 FLT4
11 endocrine/exocrine gland MP:0005379 10.4 BRCA1 BRCA2 ERBB2 ESR1 FGFR1 IL6
12 digestive/alimentary MP:0005381 10.38 BRCA1 BRCA2 ERBB2 ESR1 FGFR1 FLT4
13 nervous system MP:0003631 10.31 BRCA1 BRCA2 ERBB2 ESR1 FGF2 FGFR1
14 muscle MP:0005369 10.29 BRCA1 ERBB2 ESR1 FGF2 FGFR1 FLT1
15 neoplasm MP:0002006 10.27 BRCA1 BRCA2 ERBB2 ESR1 FGF2 IL6
16 normal MP:0002873 10.24 BRCA1 BRCA2 CLDN4 ERBB2 ESR1 FGFR1
17 limbs/digits/tail MP:0005371 10.22 BRCA1 BRCA2 ERBB2 ESR1 FGFR1 IL6ST
18 liver/biliary system MP:0005370 10.16 ESR1 FLT4 IL6 IL6ST KDR KRT19
19 craniofacial MP:0005382 10.15 ERBB2 FGFR1 KDR KRT19 MET TP53
20 reproductive system MP:0005389 10.13 BRCA1 BRCA2 ERBB2 ESR1 FGF2 FGFR1
21 no phenotypic analysis MP:0003012 10.06 ESR1 FGFR1 FLT4 KDR KRT19 MET
22 renal/urinary system MP:0005367 9.92 BRCA1 CLDN4 ESR1 FGFR1 IL6 MET
23 respiratory system MP:0005388 9.81 BRCA1 ERBB2 ESR1 IL6 KDR KRT19
24 skeleton MP:0005390 9.77 BRCA1 BRCA2 ERBB2 ESR1 FGF2 FGFR1
25 vision/eye MP:0005391 9.32 FGF2 FGFR1 FLT1 IL6 IL6ST KDR

Drugs & Therapeutics for Breast Carcinoma in Situ

Drugs for Breast Carcinoma in Situ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 140)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Medroxyprogesterone acetate Approved, Investigational Phase 3 71-58-9
2
mometasone furoate Approved, Investigational, Vet_approved Phase 3 83919-23-7
3
Oxybutynin Approved, Investigational Phase 3 5633-20-5 4634
4
Metformin Approved Phase 3 657-24-9 14219 4091
5
Pembrolizumab Approved Phase 3 1374853-91-4
6
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
7
Trastuzumab Approved, Investigational Phase 3 180288-69-1 9903
8 Neurotransmitter Agents Phase 3
9 Contraceptive Agents, Male Phase 3
10 Contraceptive Agents Phase 3
11 Contraceptives, Oral Phase 3
12
Medroxyprogesterone Phase 3 520-85-4 10631
13 Anti-Allergic Agents Phase 3
14 Dermatologic Agents Phase 3
15 Parasympatholytics Phase 3
16 Cholinergic Agents Phase 3
17 Mandelic Acids Phase 3
18 Muscarinic Antagonists Phase 3
19 Cholinergic Antagonists Phase 3
20 Hypoglycemic Agents Phase 3
21 Immunologic Factors Phase 3
22 Immunoglobulins Phase 3
23 Antibodies Phase 3
24 Antibodies, Monoclonal Phase 3
25 Immunoglobulins, Intravenous Phase 3
26 Antineoplastic Agents, Immunological Phase 3
27
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
28
Vinorelbine Approved, Investigational Phase 2 71486-22-1 60780 44424639
29
Epirubicin Approved Phase 2 56420-45-2 41867
30
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
31
Bevacizumab Approved, Investigational Phase 2 216974-75-3
32
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
33
Curcumin Approved, Experimental, Investigational Phase 2 458-37-7 969516
34
Simvastatin Approved Phase 2 79902-63-9 54454
35
Ethanol Approved Phase 2 64-17-5 702
36
Estradiol Approved, Investigational, Vet_approved Phase 2 50-28-2 5757
37
Polyestradiol phosphate Approved Phase 2 28014-46-2
38
Naltrexone Approved, Investigational, Vet_approved Phase 2 16590-41-3 5360515
39
Bazedoxifene Approved, Investigational Phase 2 198481-32-2
40
Sargramostim Approved, Investigational Phase 2 83869-56-1, 123774-72-1
41
Iodine Approved, Investigational Phase 2 7553-56-2 807
42
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
43
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
44
St. John's Wort Approved, Investigational, Nutraceutical Phase 2 84082-80-4
45
Sulforaphane Investigational Phase 2 142825-10-3, 4478-93-7 5350
46 Molgramostim Investigational Phase 2 99283-10-0
47
Afimoxifene Investigational Phase 2 68392-35-8
48 Anti-Bacterial Agents Phase 2
49 Antibiotics, Antitubercular Phase 2
50 Alkylating Agents Phase 2

Interventional clinical trials:

(show top 50) (show all 173)
# Name Status NCT ID Phase Drugs
1 An Investigator Initiated Registry of Simple Oral Therapy for Low Risk Breast Cancer (SOLR) Withdrawn NCT03238703 Phase 4 Anastrozole;Exemestane;Letrozole;Tamoxifen Citrate;Toremifene Citrate
2 Optimal Wound Care After Simplex or Modified Radical Mastectomy With or Without Axillary Lymphadenectomy Placement of a Drain Versus the Use of Adaptive Skin Sutures; a Prospective Randomised Study Unknown status NCT01509781 Phase 3
3 A Randomized Comparison Of Medroxyprogesterone Acetate (MA) And Observation For Prevention Of Endometrial Pathology In Postmenopausal Breast Cancer Patients Treated With Tamoxifen, Phase III Completed NCT00002920 Phase 3 medroxyprogesterone;tamoxifen citrate
4 Phase III Randomized Double-Blind Study of Mometasone Furoate Versus Placebo in the Prevention of Radiation Dermatitis in Breast Cancer Patients Receiving Radiation Therapy Completed NCT00438659 Phase 3 mometasone furoate
5 A Phase III Study to Evaluate Letrozole as Adjuvant Endocrine Therapy for Postmenopausal Women With Receptor (ER and/or PgR) Positive Tumors Completed NCT00004205 Phase 3 letrozole;tamoxifen citrate
6 Genetic Counseling for Newly Diagnosed Breast Cancer Patients Completed NCT00262899 Phase 3
7 A Phase III, Double-Blind, Controlled Trial of Oxybutynin in the Management of Hot Flashes Completed NCT02961790 Phase 3 Oxybutynin Chloride
8 A Clinical Trial Comparing Anastrozole With Tamoxifen in Postmenopausal Patients With Ductal Carcinoma in Situ (DCIS) Undergoing Lumpectomy With Radiation Therapy Completed NCT00053898 Phase 3 anastrozole;tamoxifen citrate
9 Testing for Atypia in Random Periareolar Fine Needle Aspiration (RPFNA) Cytology After 12 Months Metformin (1, 1-Dimethylbiguanide Hydrochloride) Chemoprevention Versus Placebo Control in Premenopausal Women Recruiting NCT01905046 Phase 3 metformin hydrochloride
10 A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy Recruiting NCT02954874 Phase 3
11 Radiotherapy Versus Low-Dose Tamoxifen Following Breast Conserving Surgery for Low-Risk and Estrogen Receptor-Positive Ductal Carcinoma in Situ of Breast: an International Open-label Randomized Non-inferiority Trial Recruiting NCT04046159 Phase 3 Low-dose tamoxifen
12 A Multicentric Phase III Trial Evaluating the Impact of a Radiation Boost (16Gy) After Breast Conserving Surgery and a Whole Breast Irradiation (50Gy) for DCIS Active, not recruiting NCT00907868 Phase 3
13 A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently With Radiation Therapy and Radiation Therapy Alone for Women With HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy Active, not recruiting NCT00769379 Phase 3
14 Phase III Trial of Tamoxifen Alone vs. Tamoxifen Plus Radiation Therapy for Good Risk Duct Carcinoma In-Situ (DCIS) of the Female Breast Active, not recruiting NCT00003857 Phase 3 tamoxifen citrate
15 International Breast Cancer Intervention Study II (IBIS-II) (DCIS) Active, not recruiting NCT00072462 Phase 3 tamoxifen citrate;Anastrozole
16 A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer Active, not recruiting NCT01272037 Phase 3 Anastrozole;Exemestane;Letrozole;Systemic Chemotherapy;Tamoxifen Citrate
17 A Phase III Trial of Accelerated Whole Breast Irradiation With Hypofractionation Plus Concurrent Boost Versus Standard Whole Breast Irradiation Plus Sequential Boost for Early-Stage Breast Cancer Active, not recruiting NCT01349322 Phase 3
18 A Randomised, Double-Blind Trial to Assess the Effects on Bone Mineral Density and Bone Biomarkers of Anastrozole When Used to Prevent Breast Cancer in Postmenopausal Women Withdrawn NCT00324714 Phase 3 risedronate sodium
19 A Multicenter Phase II Study of Docosahexaenoic Acid (DHA) in Patients With a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease Unknown status NCT01849250 Phase 2 Docosahexaenoic Acid
20 Randomised Trial Testing Observation (No Radiotherapy) Against Radiotherapy In Women With Low-Risk Completely Excised ER Positive Ductal Carcinoma In Situ (DCIS) Of The Breast On Adjuvant Endocrine Therapy Unknown status NCT00077168 Phase 2 anastrozole;tamoxifen citrate
21 "Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer" Unknown status NCT01641406 Phase 2 Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab;Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab;Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab
22 Ten Years Results of a Score System to Address Adjuvant Therapies After Breast Conserving Surgery for Ductal Carcinoma in Situ of the Breast. Completed NCT03002766 Phase 2
23 Effectiveness of Prophylactic Topical Agents for Radiation Dermatitis Completed NCT02556632 Phase 2 Curcumin-based Gel
24 A Randomized, Placebo-Controlled Phase II Clinical Trial of Omega-3 PUFA Dietary Supplementation in Patients With Stage I-III Breast Carcinoma Completed NCT01869764 Phase 2 omega-3 fatty acid
25 Phase II Study of Soy Protein to Treat Vasomotor Symptoms in Postmenopausal Women Taking Tamoxifen Completed NCT00031720 Phase 2 Tamoxifen
26 A Randomized Trial to Explore the Effect of Oral Omega 3 Fatty Acids on Atrophic Vaginitis in Postmenopausal Breast Cancer Survivors Completed NCT02150525 Phase 2
27 Validating CYP2D6 Genotype-Guided Tamoxifen Therapy for a Multiracial U.S. Population Completed NCT00764322 Phase 2 tamoxifen citrate
28 Sulforaphane: A Dietary Histone Deacetylase (HDAC) Inhibitor in Ductal Carcinoma in Situ (DCIS) Completed NCT00843167 Phase 2
29 A Trial Assessing the Effect of Simvastatin on the Pharmacokinetics of Anastrozole Completed NCT00354640 Phase 2 anastrozole;simvastatin
30 A Pilot Study of Aromatase Inhibitors for Women at Increased Risk of Breast Cancer Based on Estradiol Levels Completed NCT00090857 Phase 2 Letrozole
31 Intraoperative Radiation Therapy to the Tumor Bed for Boost Treatment After Lumpectomy Prior to Whole Breast Radiation in Breast Conservation Candidates Completed NCT00054301 Phase 2
32 Surrogate Markers of Response: A Phase II Study of Changes in Breast Density Among Postmenopausal Women Receiving Adjuvant Anastrozole Therapy Completed NCT00244959 Phase 2 anastrozole
33 Naltrexone Randomized Controlled Trial for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer Completed NCT02137252 Phase 2 Naltrexone;Sugar Pill
34 Pre-surgical Phase IIb Trial of Transdermal 4-Hydroxytamoxifen vs. Oral Tamoxifen in Women With Ductal Carcinoma in Situ of the Breast Completed NCT00952731 Phase 2 oral placebo;afimoxifene;tamoxifen citrate;placebo gel
35 Randomized Phase II Biomarker Pilot Trial of Fluvastatin Use in Women With Ductal Carcinoma in Situ (DCIS) or Stage I Breast Cancer Completed NCT00416403 Phase 2 fluvastatin sodium
36 A Phase II Study of Simvastatin in Women at High Risk for a New Breast Cancer Completed NCT00334542 Phase 2 simvastatin
37 Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS) Completed NCT01439711 Phase 2 letrozole
38 NOVEMBER (Novem- (9), BrEast Radiation), A Phase II Trial of a 9 Day Course of Whole Breast Radiotherapy for Early Stage Breast Cancer Recruiting NCT03345420 Phase 2
39 Optimizing Preventative Adjuvant Linac-Based Radiation: The OPAL Trial a Phase II/III Study of Hypofractionated Partial Breast Irradiation in Women With Early Stage Breast Cancer Recruiting NCT03077841 Phase 2
40 TBCRC 042 - A Randomized Phase II Window-of-Opportunity Trial of Ruxolitinib in Patients With High Risk and Premalignant Breast Conditions Recruiting NCT02928978 Phase 2 Ruxolitinib;Placebo (for Ruxolitinib)
41 Phase IIB Pre-Surgical Trial of Oral Tamoxifen Versus Transdermal 4-hydroxytamoxifen in Women With DCIS of the Breast Recruiting NCT02993159 Phase 2 Afimoxifene;Tamoxifen Citrate
42 Utilization of Telehealth to Improve Adherence to Adjuvant Endocrine Therapy in Breast Cancer Patients Recruiting NCT04054557 Phase 2
43 Assessing the Cosmesis and Toxicity of Partial Breast Irradiation Using Proton Beam Irradiation Recruiting NCT01245712 Phase 2
44 A Large-scale Multicenter Phase II Study Evaluating the Protective Effect of a Tissue Selective Estrogen Complex (TSEC) in Women With Newly Diagnosed Ductal Carcinoma in Situ Recruiting NCT02694809 Phase 2 Conjugated Estrogens/Bazedoxifene
45 Single Fraction Intraoperative Radiotherapy With Electrons: An Option in Breast-Conserving Operable Breast Cancer Stages 0, I and II - Prospective, Single-arm Trial Recruiting NCT01688388 Phase 1, Phase 2
46 Window Trial of Abemaciclib for Surgically Resectable, Chemotherapy-Resistant, Triple Negative Breast Cancer (a BEAUTY Study*) Recruiting NCT03979508 Phase 2 Abemaciclib
47 Safety and Feasibility of Accelerated, Hypofractionated Radiotherapy in Women With Breast Cancer: A Phase II Trial Recruiting NCT00909909 Phase 2
48 TRI-fraction Radiotherapy Utilized to Minimize Patient Hospital Trips : A Phase II Trial (TRIUMPH-T Trial) Active, not recruiting NCT02526498 Phase 2
49 A Phase II Study of Accelerated 3 Fraction Photon and Proton Partial Breast External Beam Radiotherapy and Partial Breast Brachytherapy for Early Invasive and Noninvasive Breast Cancer Active, not recruiting NCT03391388 Phase 2
50 VADIS Trial: Phase II Trial of Nelipeimut-S Peptide Vaccine in Women With DCIS of the Breast Active, not recruiting NCT02636582 Phase 2 Nelipepimut-S Plus GM-CSF Vaccine

Search NIH Clinical Center for Breast Carcinoma in Situ

Genetic Tests for Breast Carcinoma in Situ

Anatomical Context for Breast Carcinoma in Situ

The Foundational Model of Anatomy Ontology organs/tissues related to Breast Carcinoma in Situ:

19
Breast

MalaCards organs/tissues related to Breast Carcinoma in Situ:

40
Breast, Testes, Lymph Node, Bone, Skin, Endothelial, Liver

Publications for Breast Carcinoma in Situ

Articles related to Breast Carcinoma in Situ:

(show top 50) (show all 160)
# Title Authors PMID Year
1
Perineural and intraneural involvement in ductal carcinoma in-situ of breast: Case report. 61
31543222 2019
2
Ductal carcinoma in situ of breast: update 2019. 61
31472981 2019
3
Impact of Epithelial-Stromal Interactions on Peritumoral Fibroblasts in Ductal Carcinoma in Situ. 61
30816935 2019
4
MicroRNA Profiling of Salivary Duct Carcinoma Versus Her2/Neu Overexpressing Breast Carcinoma Identify miR-10a as a Putative Breast Related Oncogene. 61
30259272 2019
5
Pure secretory carcinoma in situ: a case report and literature review. 61
31443715 2019
6
"Development and validation of algorithms to differentiate ductal carcinoma in situ from invasive breast cancer within administrative claims data" by Hirth JM, Hatch SS, Lin Y, Giordano SH, Silva HC, Kuo Y. 61
30875106 2019
7
Sperm Protein Antigen 17 Expression Correlates With Lymph Node Metastasis and Worse Overall Survival in Patients With Breast Cancer. 61
31417875 2019
8
Clinical presentation of ductal carcinoma in situ of breast with intraluminal crystalloids: Radiologic-histologic correlation. 61
30241034 2018
9
Claudin-4 Expression Is Associated With Disease-Free Survival in Breast Carcinoma-in-Situ: Mean Follow-up of 8.2 Years. 61
30025999 2018
10
Sensitivity and specificity of breast cancer ICD-9-CM codes in three Italian administrative healthcare databases: a diagnostic accuracy study. 61
30037866 2018
11
Single-cell heterogeneity in ductal carcinoma in situ of breast. 61
29148540 2018
12
Androgen Receptors in Resected Ductal Carcinoma In Situ of Breast: Novel Insights With Possible Implications for Testing and Targeted Endocrine Chemoprevention Trials. 61
29489512 2018
13
Overtreatment in surgery - does it concern also the patients with ductal breast carcinoma in situ. 61
29513252 2018
14
Expression of periostin in breast cancer cells. 61
28902360 2017
15
Risk of death from breast cancer after treatment for ductal carcinoma in situ. 61
28832961 2017
16
Non-calcified ductal carcinoma in situ of the breast: comparison of diagnostic accuracy of digital breast tomosynthesis, digital mammography, and ultrasonography. 61
27837442 2017
17
Cytochrome c1 in ductal carcinoma in situ of breast associated with proliferation and comedo necrosis. 61
28394473 2017
18
Loss of Tpm4.1 leads to disruption of cell-cell adhesions and invasive behavior in breast epithelial cells via increased Rac1 signaling. 61
28431393 2017
19
Mammographic extent of microcalcifications and oestrogen receptor expression affect preoperative breast carcinoma in situ size estimation. 61
27639877 2017
20
Plasma carotenoids and the risk of premalignant breast disease in women aged 50 and younger: a nested case-control study. 61
28190250 2017
21
Ductal carcinoma in situ of breast: detection and treatment pattern in Hong Kong. 61
27779099 2017
22
Paradigm Shift toward Reducing Overtreatment of Ductal Carcinoma In Situ of Breast. 61
28894698 2017
23
Reproductive factors and the risk of triple-negative breast cancer in white women and African-American women: a pooled analysis. 61
28086982 2017
24
Breast carcinoma in situ: An observational study of tumor subtype, treatment and outcomes. 61
27926499 2017
25
Ductal Breast Carcinoma In Situ: Mammographic Features and Its Relation to Prognosis and Tumour Biology in a Population Based Cohort. 61
28286675 2017
26
Differential distribution of immune cells in breast invasive carcinoma vs. breast carcinoma in situ and its significance in interpretation of immune surveillance. 61
31966621 2017
27
[Chinese expert consensus on the diagnosis and treatment of breast carcinoma in situ]. 61
27998472 2016
28
Loss of MLCK leads to disruption of cell-cell adhesion and invasive behavior of breast epithelial cells via increased expression of EGFR and ERK/JNK signaling. 61
26876209 2016
29
Tumor characteristics of ductal carcinoma in situ of breast visualized on [F-18] fluorodeoxyglucose-positron emission tomography/computed tomography: Results from a retrospective study. 61
27648168 2016
30
Different Biological Action of Oleic Acid in ALDHhigh and ALDHlow Subpopulations Separated from Ductal Carcinoma In Situ of Breast Cancer. 61
27589390 2016
31
Possible Prognostic Role of HER2/Neu in Ductal Carcinoma In Situ and Atypical Ductal Proliferative Lesions of the Breast. 61
27644608 2016
32
Cancer statistics: Breast cancer in situ. 61
26431342 2015
33
Octreotide LAR and tamoxifen versus tamoxifen in phase III randomize early breast cancer trials: NCIC CTG MA.14 and NSABP B-29. 61
26276354 2015
34
Basal cytokeratin phenotypes of myoepithelial cells indicates the origin of ductal carcinomas in situ of the breast. 61
26336082 2015
35
The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study. 61
26062614 2015
36
Context-Dependent Function of Myoepithelial Cells in Breast Morphogenesis and Neoplasia. 61
28680803 2015
37
Acoustic radiation force impulse elastography for differentiation of malignant and benign breast lesions: a meta-analysis. 61
26131049 2015
38
A prospective cohort study on postoperative radiotherapy with TomoDirect using simultaneous integrated boost technique in early breast cancer. 61
25410791 2014
39
Armc8 expression was elevated during atypia-to-carcinoma progression and associated with cancer development of breast carcinoma. 61
25119601 2014
40
Relative expression of hMena11a and hMenaINV splice isoforms is a useful biomarker in development and progression of human breast carcinoma. 61
25109497 2014
41
The CDC42-interacting protein 4 controls epithelial cell cohesion and tumor dissemination. 61
25203208 2014
42
Determination of HER2/neu status: a pilot study comparing HER2/neu dual in situ hybridization DNA probe cocktail assay performed on cell blocks to immunohistochemisty and fluorescence in situ hybridization performed on histologic specimens. 61
24678687 2014
43
[The relationship between passive smoking, breast cancer risk and n-acetyltransferase 2 (NAT2)]. 61
24791559 2014
44
[Sentinel lymph node metastasis in patients with ductal breast carcinoma in situ]. 61
25312311 2014
45
Diagnostic utility of E-cadherin and P120 catenin cocktail immunostain in distinguishing DCIS from LCIS. 61
24966968 2014
46
High-resolution 3D micro-CT imaging of breast microcalcifications: a preliminary analysis. 61
24393444 2014
47
Elevated lipogenesis in epithelial stem-like cell confers survival advantage in ductal carcinoma in situ of breast cancer. 61
23208501 2013
48
Comparison of two breast carcinomas: ductal carcinoma in situ and lobular carcinoma in situ. 61
24147320 2013
49
[Expression Wnt2 in breast cancer tissues and sera of the patients]. 61
23746249 2013
50
Prospective study on physical activity and risk of in situ breast cancer. 61
23074288 2012

Variations for Breast Carcinoma in Situ

Expression for Breast Carcinoma in Situ

Search GEO for disease gene expression data for Breast Carcinoma in Situ.

Pathways for Breast Carcinoma in Situ

Pathways related to Breast Carcinoma in Situ according to GeneCards Suite gene sharing:

(show top 50) (show all 79)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.25 VEGFC VEGFA TP53 SDC1 PGR MET
2
Show member pathways
13.9 VEGFC TP53 MET KDR IL6ST IL6
3
Show member pathways
13.88 VEGFC VEGFA TP53 OSM MET KDR
4
Show member pathways
13.74 TP53 OSM MET KDR IL6ST IL6
5
Show member pathways
13.71 VEGFC VEGFA TP53 MET KDR IL6
6
Show member pathways
13.63 VEGFC VEGFA TP53 MET KDR IL6
7
Show member pathways
13.62 VEGFC MET KDR IL6 FLT4 FLT1
8
Show member pathways
13.51 VEGFC TP53 OSM MET KDR IL6
9
Show member pathways
13.45 VEGFA TP53 OSM MET IL6ST IL6
10
Show member pathways
13.42 VEGFC MET KDR IL6 FLT4 FLT1
11
Show member pathways
13.41 VEGFC OSM MET KDR IL6 FLT4
12
Show member pathways
13.37 VEGFC VEGFA MET KDR IL6 FLT4
13
Show member pathways
13.18 VEGFC TP53 MET KDR IL6 FLT4
14
Show member pathways
13.15 VEGFC MET KDR IL6 FLT4 FLT1
15
Show member pathways
13.02 MET KDR FLT4 FLT1 FGFR1 ERBB2
16
Show member pathways
13 VEGFC VEGFA MET KDR FLT4 FLT1
17
Show member pathways
12.85 VEGFC VEGFA MET KDR FLT4 FLT1
18
Show member pathways
12.81 VEGFC MET KDR IL6 FLT4 FLT1
19
Show member pathways
12.78 TP53 MET FGFR1 FGF2 ERBB2
20
Show member pathways
12.78 TP53 MET FGFR1 FGF2 ESR1 ERBB2
21
Show member pathways
12.77 TP53 SDC1 MET ESR1 ERBB2
22
Show member pathways
12.75 VEGFA TP53 MET KDR IL6 FGF2
23
Show member pathways
12.73 VEGFC VEGFA PGR KRT19 ESR1
24 12.73 VEGFC VEGFA TP53 MET KDR FLT4
25
Show member pathways
12.69 TP53 PGR MET FLT4 FGFR1 FGF2
26
Show member pathways
12.64 VEGFC VEGFA TP53 KDR FLT1 FGFR1
27 12.61 VEGFA TP53 MET ERBB2 BRCA1
28
Show member pathways
12.59 TP53 SDC1 MET KDR FLT4 FLT1
29
Show member pathways
12.58 TP53 MET KDR FLT4 FLT1 FGFR1
30
Show member pathways
12.49 VEGFC VEGFA KDR FLT4 FLT1
31
Show member pathways
12.49 VEGFC MET KDR IL6 FLT4 FLT1
32
Show member pathways
12.49 VEGFC VEGFA MET KDR FLT4 FLT1
33
Show member pathways
12.48 VEGFA SDC1 KDR ESR1 BRCA1
34 12.46 VEGFC VEGFA TP53 MET IL6ST IL6
35
Show member pathways
12.39 TP53 SDC1 IL6 FGFR1 FGF2
36
Show member pathways
12.37 TP53 IL6ST IL6 ERBB2
37
Show member pathways
12.36 VEGFA TP53 OSM IL6ST
38
Show member pathways
12.34 TP53 MET KDR IL6ST FLT4 FLT1
39 12.32 TP53 MET IL6 FLT1
40
Show member pathways
12.32 VEGFC TP53 MET KDR IL6 FLT4
41 12.27 VEGFA TP53 ESR1 BRCA2 BRCA1
42
Show member pathways
12.27 VEGFC VEGFA TP53 OSM MET KDR
43 12.2 VEGFA MET KRT19 KDR IL6 FGF2
44 12.17 VEGFA TP53 SDC1 KDR
45 12.12 VEGFA TP53 SDC1 MET KDR FGFR1
46 12.11 VEGFA TP53 OSM IL6 FGF2
47 12.04 VEGFA IL6 FLT1 ERBB2
48 12.03 VEGFC MET KDR FLT4 FLT1 FGFR1
49
Show member pathways
12.02 VEGFC VEGFA KDR FLT4 FLT1
50 11.97 VEGFC KDR FLT4 FLT1 FGFR1 FGF2

GO Terms for Breast Carcinoma in Situ

Cellular components related to Breast Carcinoma in Situ according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.86 SDC1 MET KDR FLT4 FLT1 FGFR1
2 extracellular region GO:0005576 9.73 VEGFC VEGFA SDC1 OSM MET KDR
3 basal plasma membrane GO:0009925 9.5 MET ERBB2 CLDN4
4 receptor complex GO:0043235 9.17 MET KDR IL6ST FLT4 FLT1 FGFR1
5 interleukin-6 receptor complex GO:0005896 9.16 IL6ST IL6

Biological processes related to Breast Carcinoma in Situ according to GeneCards Suite gene sharing:

(show top 50) (show all 62)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.35 VEGFC VEGFA PGR MET IL6ST IL6
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.27 VEGFA TP53 PGR OSM MET IL6
3 multicellular organism development GO:0007275 10.27 VEGFC VEGFA OSM MET KDR FLT4
4 phosphorylation GO:0016310 10.18 MET KDR FLT4 FLT1 FGFR1 ERBB2
5 positive regulation of transcription, DNA-templated GO:0045893 10.17 TP53 IL6 FGF2 ESR1 BRCA2 BRCA1
6 protein phosphorylation GO:0006468 10.16 MET KDR FLT4 FLT1 FGFR1 ERBB2
7 negative regulation of apoptotic process GO:0043066 10.15 VEGFA TP53 KDR IL6ST IL6 FLT4
8 positive regulation of gene expression GO:0010628 10.12 VEGFA TP53 IL6 ERBB2 BRCA1
9 negative regulation of gene expression GO:0010629 10.09 VEGFA TP53 PGR KDR FGFR1 FGF2
10 cytokine-mediated signaling pathway GO:0019221 10.08 VEGFA TP53 SDC1 OSM IL6ST IL6
11 cell migration GO:0016477 10.06 SDC1 MET KDR FLT1 FGFR1
12 positive regulation of cell migration GO:0030335 10.06 VEGFC VEGFA KDR FLT1 CLDN4
13 positive regulation of protein phosphorylation GO:0001934 10.04 VEGFC VEGFA KDR FLT4 ERBB2
14 positive regulation of protein kinase B signaling GO:0051897 10.04 OSM MET FGFR1 FGF2 ESR1 ERBB2
15 protein autophosphorylation GO:0046777 10.03 KDR FLT4 FLT1 FGFR1 ERBB2
16 positive regulation of angiogenesis GO:0045766 10 VEGFC VEGFA KDR FLT1 FGF2 BRCA1
17 angiogenesis GO:0001525 10 VEGFC VEGFA KDR FLT4 FLT1 FGFR1
18 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.96 VEGFA TP53 OSM IL6
19 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.96 OSM KDR FLT1 FGFR1
20 positive regulation of endothelial cell proliferation GO:0001938 9.96 VEGFC VEGFA KDR FLT4 FGF2
21 hematopoietic progenitor cell differentiation GO:0002244 9.95 TP53 KDR FLT4 FLT1
22 peptidyl-tyrosine phosphorylation GO:0018108 9.95 MET KDR FLT4 FLT1 FGFR1 ERBB2
23 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.94 VEGFA OSM IL6ST IL6
24 positive chemotaxis GO:0050918 9.91 VEGFC VEGFA MET FGF2
25 positive regulation of cell division GO:0051781 9.91 VEGFC VEGFA OSM FGF2
26 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.91 VEGFC VEGFA KDR FLT4 FLT1
27 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.91 MET KDR FLT4 FLT1 FGFR1 ERBB2
28 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.9 VEGFA KDR FLT4 FLT1
29 double-strand break repair GO:0006302 9.89 TP53 BRCA2 BRCA1
30 positive regulation of epithelial cell proliferation GO:0050679 9.89 VEGFC VEGFA ERBB2
31 response to estrogen GO:0043627 9.89 KRT19 ESR1 BRCA1
32 positive regulation of MAP kinase activity GO:0043406 9.89 VEGFA FLT1 FGFR1 FGF2 ERBB2
33 positive regulation of endothelial cell migration GO:0010595 9.88 VEGFA KDR FLT4
34 positive regulation of vascular endothelial growth factor production GO:0010575 9.88 IL6ST IL6 FLT4 BRCA1
35 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.85 VEGFA KDR FGF2
36 regulation of angiogenesis GO:0045765 9.85 IL6 FGF2 ERBB2
37 blood vessel morphogenesis GO:0048514 9.85 FLT4 FLT1 FGFR1
38 cell migration involved in sprouting angiogenesis GO:0002042 9.83 VEGFA KDR FGF2
39 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.8 TP53 BRCA2 BRCA1
40 positive regulation of acute inflammatory response GO:0002675 9.8 OSM IL6ST IL6
41 positive regulation of blood vessel endothelial cell migration GO:0043536 9.8 VEGFC VEGFA KDR FGFR1 FGF2
42 chordate embryonic development GO:0043009 9.77 FGFR1 BRCA2 BRCA1
43 positive regulation of positive chemotaxis GO:0050927 9.73 VEGFA KDR
44 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.73 TP53 IL6
45 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.73 TP53 ESR1
46 positive regulation of kinase activity GO:0033674 9.73 MET KDR FLT4 FLT1 FGFR1 ERBB2
47 positive regulation of endothelial cell chemotaxis GO:2001028 9.72 MET FGF2
48 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 9.72 TP53 ESR1
49 positive regulation of protein kinase C signaling GO:0090037 9.72 VEGFA FLT4
50 vascular wound healing GO:0061042 9.72 VEGFA KDR

Molecular functions related to Breast Carcinoma in Situ according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.4 VEGFC VEGFA TP53 SDC1 PGR OSM
2 kinase activity GO:0016301 10 MET KDR FLT4 FLT1 FGFR1 ERBB2
3 protein kinase activity GO:0004672 9.95 MET KDR FLT4 FLT1 FGFR1 ERBB2
4 cytokine activity GO:0005125 9.86 VEGFA OSM IL6 FGF2
5 growth factor activity GO:0008083 9.83 VEGFC VEGFA OSM IL6 FGF2
6 protein phosphatase binding GO:0019903 9.76 TP53 MET FLT4 ERBB2
7 protein tyrosine kinase activity GO:0004713 9.73 MET KDR FLT4 FLT1 FGFR1 ERBB2
8 chemoattractant activity GO:0042056 9.67 VEGFC VEGFA FGF2
9 interleukin-6 receptor binding GO:0005138 9.55 IL6ST IL6
10 growth factor binding GO:0019838 9.55 KDR IL6ST FLT4 FLT1 ERBB2
11 vascular endothelial growth factor receptor binding GO:0005172 9.54 VEGFC VEGFA
12 vascular endothelial growth factor binding GO:0038085 9.54 KDR FLT4 FLT1
13 receptor-receptor interaction GO:0090722 9.51 FGFR1 FGF2
14 vascular endothelial growth factor-activated receptor activity GO:0005021 9.5 KDR FLT4 FLT1
15 identical protein binding GO:0042802 9.47 VEGFA TP53 SDC1 PGR MET KDR
16 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.43 MET KDR FLT4 FLT1 FGFR1 ERBB2

Sources for Breast Carcinoma in Situ

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....